Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma-Reference-Cited by-全球学者库

Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma

Published:2024-01-10 Issue: Volume: Page:
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Yan Fang¹^ORCID,Chen Longpei¹^ORCID,Ying Mingzhen¹,Li Jie¹,Fu Qiang¹

Affiliation:

1. Department of Oncology, Shanghai Changhai Hospital, No. 168 Changhai Road, Shanghai, 200433, China

Abstract

Objective: This research aimed to assess the efficacy and safety of pembrolizumab (PBL) combined with albumin-bound paclitaxel (ab-Pac) and nedaplatin (NDP) for advanced esophageal squamous cell carcinoma (ESCC). Methods: A total of 47 ESCC patients were administered PBL or NDP on day 1 and ab-Pac on days 1 and 8, every 21 days for one cycle. Tumor and toxicities were evaluated every two cycles and every cycle, respectively. Results: The objective response rate was 68.1% and the disease control rate was 100%. The median follow-up was 16.7 months; median progression-free and overall survival were 12.6 and 19.9 months, respectively. Conclusion: The combination of PBL with ab-Pac and NDP proved to be an effective and safe treatment regimen for advanced ESCC.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2023-0188

Reference54 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer incidence and mortality in China, 2016

3. Advances in targeted therapy and immunotherapy for esophageal cancer

4. National Comprehensive Cancer Network. NCCN Guidelines in esophageal and esophagogastric junction cancers, version 3 (2023). www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

5. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis